Biogen, Sanofi and Novartis stoke oral MS drug rivalry with clinical data

Three contenders in the oral multiple sclerosis drug race have spotlighted their rival therapies this week. Biogen Idec ($BIIB), which revealed analysis from two Phase III studies of its blockbuster h…

---

New FDA lung cancer OK for Celgene’s Abraxane should boost sales

When Celgene ($CELG) bought out Abraxis two years ago for an eye-popping $2.9 billion, it set out to prove that it could do a better job selling the drug for breast cancer while expanding the drug's u…

---

Pfizer aims to keep CEO off the stand in Chantix trial

Pfizer doesn't want CEO Ian Read to take the stand in a Chantix liability suit. That's not unusual; Johnson & Johnson fought a request that CEO Alex Gorsky testify in person in a trial over allege…

---

Will GlaxoSmithKline’s transparency pledge force pharma rivals to open up?

Stung by intense criticism of its past penchant for secrecy and data manipulation, GlaxoSmithKline CEO Andrew Witty today took the transparency pledge, vowing to shine a light on all trial results--go…

---